Literature DB >> 26497338

Benign prostatic hyperplasia: epidemiology, economics and evaluation.

Camille Vuichoud1, Kevin R Loughlin.   

Abstract

INTRODUCTION: Benign prostatic hyperplasia (BPH) is arguably the most common benign disease of mankind. As men age, the prostate inexorably grows often causing troubling symptoms causing them to seek out care. While traditionally treated by transurethral resection or open surgical removal of the hypertrophied adenoma, today the urologist has numerous medical, surgical and minimally invasive techniques available. In this supplement The Canadian Journal of Urology provides a review of the various techniques and medications available today.
MATERIALS AND METHODS: As an introduction to the supplement, the aim of this article is to review the epidemiology and economy of BPH as well as its natural history and diagnosis. A systematic review of available literature was looking for articles on BPH and its epidemiology, economics, natural history and management using PubMed database.
RESULTS: The prevalence of this condition is increasing with the population aging and so does the economic burden. The exact etiology of this condition is unknown, but some risk factors have been identified. The diagnostic and treatment of this very common disease should rely on a strong collaboration between primary care physician and urologist.
CONCLUSION: There are multiple options in treating BPH including medical, surgical and newer minimally invasive options. The challenge with having a variety of options is to review them with the patient and help the patient select the best treatment option for their condition.

Entities:  

Mesh:

Year:  2015        PMID: 26497338

Source DB:  PubMed          Journal:  Can J Urol        ISSN: 1195-9479            Impact factor:   1.344


  67 in total

1.  Prostatic osteopontin expression is associated with symptomatic benign prostatic hyperplasia.

Authors:  Petra Popovics; Wisam N Awadallah; Sarah E Kohrt; Thomas C Case; Nicole L Miller; Emily A Ricke; Wei Huang; Marisol Ramirez-Solano; Qi Liu; Chad M Vezina; Robert J Matusik; William A Ricke; Magdalena M Grabowska
Journal:  Prostate       Date:  2020-05-01       Impact factor: 4.104

2.  CUA guideline on adult overactive bladder.

Authors:  Jacques Corcos; Mikolaj Przydacz; Lysanne Campeau; Gary Gray; Duane Hickling; Christiane Honeine; Sidney B Radomski; Lynn Stothers; Adrian Wagg; Frcp Lond
Journal:  Can Urol Assoc J       Date:  2017-05-09       Impact factor: 1.862

Review 3.  State of the art of prostatic arterial embolization for benign prostatic hyperplasia.

Authors:  Mario Petrillo; Filippo Pesapane; Enrico Maria Fumarola; Ilaria Emili; Marzia Acquasanta; Francesca Patella; Salvatore Alessio Angileri; Umberto G Rossi; Igor Piacentini; Antonio Maria Granata; Anna Maria Ierardi; Gianpaolo Carrafiello
Journal:  Gland Surg       Date:  2018-04

Review 4.  Rezum: a new transurethral water vapour therapy for benign prostatic hyperplasia.

Authors:  Jennifer Westwood; Robert Geraghty; Patrick Jones; Bhavan P Rai; Bhaskar K Somani
Journal:  Ther Adv Urol       Date:  2018-08-12

Review 5.  The effect of diet on BPH, LUTS and ED.

Authors:  Mahmoud ElJalby; Dominique Thomas; Dean Elterman; Bilal Chughtai
Journal:  World J Urol       Date:  2018-11-23       Impact factor: 4.226

6.  National trends in the use of PSA, urinalysis, and digital rectal exam for evaluation of lower urinary tract symptoms in men.

Authors:  James Doolin; Zachary A Reese; Kenneth J Mukamal
Journal:  World J Urol       Date:  2020-05-24       Impact factor: 4.226

Review 7.  Prostate artery embolization: a new, minimally invasive treatment for lower urinary tract symptoms secondary to prostate enlargement.

Authors:  Drew Maclean; Ben Maher; Sachin Modi; Mark Harris; Jonathan Dyer; Bhaskar Somani; Nigel Hacking; Timothy Bryant
Journal:  Ther Adv Urol       Date:  2017-07-10

Review 8.  Costs of Managing Benign Prostatic Hyperplasia in the Office and Operating Room.

Authors:  Bradley C Gill; James C Ulchaker
Journal:  Curr Urol Rep       Date:  2018-07-19       Impact factor: 3.092

Review 9.  Prostatic Urethral Lift Versus Transurethral Resection of the Prostate (TURP).

Authors:  Giuseppe Magistro; Christian G Stief; Christian Gratzke
Journal:  Curr Urol Rep       Date:  2017-08-29       Impact factor: 3.092

10.  Urinary and sexual function after treatment with temporary implantable nitinol device (iTind) in men with LUTS: 6-month interim results of the MT-06-study.

Authors:  Cosimo De Nunzio; Francesco Cantiello; Cristian Fiori; Fabio Crocerossa; Piero Tognoni; Daniele Amparore; Valeria Baldassarri; Javier Reinoso Elbers; Fernando Gomez Sancha; Francesco Porpiglia
Journal:  World J Urol       Date:  2020-08-26       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.